<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cytokines and inflammation</journal-id><journal-title-group><journal-title xml:lang="en">Cytokines and inflammation</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитокины и воспаление</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1684-7849</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">627073</article-id><article-id pub-id-type="doi">10.17816/CI627073</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Dependence of cytokine concentration in coproextracts in children with inflammatory bowel diseases on disease activity</article-title><trans-title-group xml:lang="ru"><trans-title>Зависимость концентрации цитокинов в копроэкстрактах детей с воспалительными заболеваниями кишечника от активности заболевания</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9981-4762</contrib-id><contrib-id contrib-id-type="spin">8523-5018</contrib-id><name-alternatives><name xml:lang="en"><surname>Toptygina</surname><given-names>Anna P.</given-names></name><name xml:lang="ru"><surname>Топтыгина</surname><given-names>Анна Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>toptyginaanna@rambler.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8923-4652</contrib-id><contrib-id contrib-id-type="spin">3647-4967</contrib-id><name-alternatives><name xml:lang="en"><surname>Semikina</surname><given-names>Elena L.</given-names></name><name xml:lang="ru"><surname>Семикина</surname><given-names>Елена Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>semikinaelena@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8162-2957</contrib-id><contrib-id contrib-id-type="spin">2723-8402</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsvetkova</surname><given-names>Valeria S.</given-names></name><name xml:lang="ru"><surname>Цветкова</surname><given-names>Валерия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>tsvetkova.valerie@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0250-343X</contrib-id><contrib-id contrib-id-type="spin">2979-7431</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasnovidova</surname><given-names>Anastasia E.</given-names></name><name xml:lang="ru"><surname>Красновидова</surname><given-names>Анастасия Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dr.krasnovidova@yandex.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4905-2373</contrib-id><contrib-id contrib-id-type="spin">9507-7419</contrib-id><name-alternatives><name xml:lang="en"><surname>Potapov</surname><given-names>Alexander S.</given-names></name><name xml:lang="ru"><surname>Потапов</surname><given-names>Александр Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>potapov@nczd.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Medical Research Center of Children’s Health</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр здоровья детей</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-18" publication-format="electronic"><day>18</day><month>12</month><year>2023</year></pub-date><volume>20</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>40</fpage><lpage>48</lpage><history><date date-type="received" iso-8601-date="2024-02-16"><day>16</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-03-13"><day>13</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Toptygina A.P., Semikina E.L., Tsvetkova V.S., Krasnovidova A.E., Potapov A.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Топтыгина А.П., Семикина Е.Л., Цветкова В.С., Красновидова А.Е., Потапов А.С.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Toptygina A.P., Semikina E.L., Tsvetkova V.S., Krasnovidova A.E., Potapov A.S.</copyright-holder><copyright-holder xml:lang="ru">Топтыгина А.П., Семикина Е.Л., Цветкова В.С., Красновидова А.Е., Потапов А.С.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-05-18"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://cijournal.ru/1684-7849/article/view/627073">https://cijournal.ru/1684-7849/article/view/627073</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold><italic> </italic>Inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) affect more than 6.8 million people. The key factor in the immunopathogenesis of these diseases is the intestinal wall infiltration by various immunocompetent cells and their proinflammatory cytokine production.</p> <p><bold>AIM:</bold><italic> </italic>To compare the levels of 14 cytokines in the coproextracts of patients with IBD with various disease activities.</p> <p><bold>MATERIALS AND METHODS:</bold><italic> </italic>The examined cohort comprised 30 children with CD, 33 with UC, and 20 healthy children (control group). UC and CD were diagnosed based on generally accepted clinical and endoscopic criteria. The concentrations of 14 cytokines (IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, and TNF) in aqueous-salt coproextrates were determined using the multiplex method (MagPix, BioRad, USA).</p> <p><bold>RESULTS:</bold><italic> </italic>The levels of all studied cytokines were significantly increased in all sick children, even in remission, compared with the control group. The concentration of proinflammatory cytokines (TNF, IL-1β, IL-6, IL-17A, and IL-17F) consistently decreased with the decrease in disease activity in the coproextracts of patients with CD and UC. Furthermore, the IL-22, IL-33, and IL-10 levels increased as the inflammation activity decreased.</p> <p><bold>CONCLUSIONS:</bold><italic> </italic>The lack of normalization of cytokine levels in remission raises the question of the need for further study of IBD immunopathogenesis and the search for new therapeutic approaches.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Воспалительными заболеваниями кишечника, такими как болезнь Крона и язвенный колит, страдают более 6,8 млн человек. Ключевым моментом в иммунопатогенезе этих заболеваний считают инфильтрацию стенки кишечника различными иммунокомпетентными клетками и продукцию ими провоспалительных цитокинов.</p> <p><bold>Цель исследования</bold> — сопоставление уровней 14 цитокинов в копроэкстрактах больных воспалительными заболеваниями кишечника с различной активностью заболевания.</p> <p><bold>Методы.</bold> Когорту обследованных составили 30 детей с болезнью Крона, 33 ребенка с язвенным колитом и 20 условно здоровых детей контрольной группы. Диагнозы «болезнь Крона» и «язвенный колит» были установлены согласно общепринятым клиническим и эндоскопическим критериям. Концентрацию 14 цитокинов (IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ и TNF) в водно-солевых копроэкстрактах определяли с помощью мультиплексного метода (MagPix, BioRad, США).</p> <p><bold>Результаты.</bold> Показано, что уровни всех исследованных цитокинов были значимо повышены у всех больных детей, даже в ремиссии, по сравнению с контрольной группой. Уровни провоспалительных цитокинов (TNF, IL-1β, IL-6, IL-17A, IL-17F) последовательно снижались в копроэкстрактах пациентов с болезнью Крона и язвенным колитом по мере снижения активности заболевания. В то же время уровни IL-22, IL-33 и IL-10, напротив, повышались по мере снижения активности воспаления.</p> <p><bold>Заключение.</bold> Отсутствие нормализации уровней цитокинов в ремиссии поднимает вопрос о необходимости дальнейшего изучения иммунопатогенеза воспалительных заболеваний кишечника и поиска новых терапевтических подходов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>Crohn’s disease</kwd><kwd>ulcerative colitis</kwd><kwd>inflammatory bowel disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>болезнь Крона</kwd><kwd>язвенный колит</kwd><kwd>воспалительные заболевания кишечника</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5–17. doi: 10.1016/j.cyto.2014.09.011</mixed-citation><mixed-citation xml:lang="ru">Raphael I., Nalawade S., Eagar T.N., Forsthuber T.G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases // Cytokine. 2015. Vol. 74, N. 1. P. 5–17. doi: 10.1016/j.cyto.2014.09.011</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Cao H, Diao J, Liu H, et al. The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2023;29(5):818–829. doi: 10.1093/ibd/izac199</mixed-citation><mixed-citation xml:lang="ru">Cao H., Diao J., Liu H., et al. The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases // Inflamm Bowel Dis. 2023. Vol. 29, N 5. P. 818–829. doi: 10.1093/ibd/izac199</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Ghilas S, O’Keefe R, Mielke LA, et al. Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease. Front Immunol. 2022;13:944982. doi: 10.3389/fimmu.2022.944982</mixed-citation><mixed-citation xml:lang="ru">Ghilas S., O’Keefe R., Mielke L.A., et al. Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease // Front Immunol. 2022. Vol. 13. P. 944982. doi: 10.3389/fimmu.2022.944982</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells. 2021;10(1):111. doi: 10.3390/cells10010111</mixed-citation><mixed-citation xml:lang="ru">Mahapatro M., Erkert L., Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut // Cells. 2021. Vol. 10, N 1. P. 111. doi: 10.3390/cells10010111</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Katsandegwaza B, Horsnell W, Smith K. Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease. Int J Mol Sci. 2022;23(16):9344. doi: 10.3390/ijms23169344</mixed-citation><mixed-citation xml:lang="ru">Katsandegwaza B., Horsnell W., Smith K. Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease // Int J Mol Sci. 2022. Vol. 23, N 16. P. 9344. doi: 10.3390/ijms23169344</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Toptygina AP, Semikina EL, Bobyleva GV, Miroshkina LV, Petrichuk SV. Cytokine profile in children with inflammatory bowel disease. Biochemistry. 2014;79(12):1673–1679. (In Russ). EDN: TQQMVZ</mixed-citation><mixed-citation xml:lang="ru">Топтыгина А.П., Семикина Е.Л., Бобылева Г.В., Мирошкина Л.В., Петричук С.В. Цитокиновый профиль у детей с воспалительными заболеваниями кишечника // Биохимия. 2014. T. 79, № 12. C. 1673–1679. EDN: TQQMVZ</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13(12):1174–1181. doi: 10.1016/j.autrev.2014.08.019</mixed-citation><mixed-citation xml:lang="ru">Singh R.P., Hasan S., Sharma S., et al. Th17 cells in inflammation and autoimmunity // Autoimmun Rev. 2014. Vol. 13, N 12. P. 1174–1181. doi: 10.1016/j.autrev.2014.08.019</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Zhao J, Lu Q, Liu Y, et al. Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies. J Immunol Res. 2021;2021:8816041. doi: 10.1155/2021/8816041</mixed-citation><mixed-citation xml:lang="ru">Zhao J., Lu Q., Liu Y., et al. Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies // J Immunol Res. 2021. Vol. 2021. P. 8816041. doi: 10.1155/2021/8816041</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Toskas A, Milias S, Delis G, et al. Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study. Diagnostics. 2023;13(13):2185. doi: 10.3390/diagnostics13132185</mixed-citation><mixed-citation xml:lang="ru">Toskas A., Milias S., Delis G., et al. Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study // Diagnostics. 2023. Vol. 13, N 13. P. 2185. doi: 10.3390/diagnostics13132185</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Zorzi F, Monteleone I, Sarra M, et al. Distinct profiles of effector cytokines mark the different phases of Crohn’s disease. PLoS ONE. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562</mixed-citation><mixed-citation xml:lang="ru">Zorzi F., Monteleone I., Sarra M., et al. Distinct profiles of effector cytokines mark the different phases of Crohn’s disease // PLoS ONE. 2013. Vol. 8, N 1. P. e54562. doi: 10.1371/journal.pone.0054562</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Shohan M, Dehghani R, Khodadadi A, et al. Interleukin-22 and intestinal homeostasis: Protective or destructive? IUBMB Life 2020;72(8):1585–1602. doi: 10.1002/iub.2295</mixed-citation><mixed-citation xml:lang="ru">Shohan M., Dehghani R., Khodadadi A., et al. Interleukin-22 and intestinal homeostasis: Protective or destructive? // IUBMB Life 2020. Vol. 72, N 8. P. 1585–1602. doi: 10.1002/iub.2295</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Monticelli LA, Osborne LC, Noti M, et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA. 2015;112(34):10762–10767. doi: 10.1073/pnas.1509070112</mixed-citation><mixed-citation xml:lang="ru">Monticelli L.A., Osborne L.C., Noti M., et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions // Proc Natl Acad Sci USA. 2015. Vol. 112, N 34. P. 10762–10767. doi: 10.1073/pnas.1509070112</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Mantani PT, Vallejo J, Ljungcrantz I, et al. Interleukin-25 reduces Th17 cells and inflammatory responses in human peripheral blood mononuclear cells. Hum Immunol. 2018;79(9):685–692. doi: 10.1016/j.humimm.2018.06.008</mixed-citation><mixed-citation xml:lang="ru">Mantani P.T., Vallejo J., Ljungcrantz I., et al. Interleukin-25 reduces Th17 cells and inflammatory responses in human peripheral blood mononuclear cells // Hum Immunol. 2018. Vol. 79, N 9. P. 685–692. doi: 10.1016/j.humimm.2018.06.008</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Fina D, Franzè E, Rovedatti L, et al. Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut. Mucosal Immunol. 2011;4(2):239–244. doi: 10.1038/mi.2010.68</mixed-citation><mixed-citation xml:lang="ru">Fina D., Franzè E., Rovedatti L., et al. Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut // Mucosal Immunol. 2011. Vol. 4, N 2. P. 239–244. doi: 10.1038/mi.2010.68</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Su J, Chen T, Ji XY, et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in flammatory bowel disease. Inflamm Bowel Dis. 2013;19(4):720–728. doi: 10.1097/MIB.0b013e3182802a76</mixed-citation><mixed-citation xml:lang="ru">Su J., Chen T., Ji X.Y., et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in flammatory bowel disease // Inflamm Bowel Dis. 2013. Vol. 19, N 4. P. 720–728. doi: 10.1097/MIB.0b013e3182802a76</mixed-citation></citation-alternatives></ref></ref-list></back></article>
